guest ::
| Home > Publications database > Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas |
| Home > Publications database > Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas |
| Journal Article | FZJ-2023-00223 |
; ; ; ; ; ; ;
2023
Springer Science + Business Media B.V
Dordrecht [u.a.]
This record in other databases: 
Please use a persistent id in citations: http://hdl.handle.net/2128/34581 doi:10.1007/s11060-022-04218-x
Abstract: PET imaging using radiolabeled amino acids in addition to MRI has become a valuable diagnostic tool in the clinical management of patients with brain tumors. This review provides a comprehensive overview of PET studies in glioma patients with a mutation in the isocitrate dehydrogenase gene (IDH). A considerable fraction of these tumors typically show no contrast enhancement on MRI, especially when classified as grade 2 according to the World Health Organization classification of Central Nervous System tumors. Major diagnostic challenges in this situation are differential diagnosis, target definition for diagnostic biopsies, delineation of glioma extent for treatment planning, differentiation of treatment-related changes from tumor progression, and the evaluation of response to alkylating agents. The main focus of this review is the role of amino acid PET in this setting. Furthermore, in light of clinical trials using IDH inhibitors targeting the mutated IDH enzyme for treating patients with IDH-mutant gliomas, we also aim to give an outlook on PET probes specifically targeting the IDH mutation, which appear potentially helpful for response assessment.
; 
; 
; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DEAL Springer ; Essential Science Indicators ; IF < 5 ; JCR ; Nationallizenz
; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |
PDF
Fulltext by OpenAccess repository